Radiopharmaceutical developer DraxImage has received Food and Drug Administration approval to begin a phase II clinical study of its Infecton molecular imaging agent, designed to detect and localize difficult-to-diagnose infection in the body.
The multicenter trial will examine patients suffering from bacterial osteomyelitis, according to the firm, which is a subsidiary of Mississauga, Ontario-based Draxis Health. Enrollment will begin immediately and continue into the beginning of 2005, DraxImage said.
Two other Infecton trials are under way in Canada, involving diabetic patients with bacterial infections of the foot, and patients with either known soft-tissue infections or chronic inflammatory conditions.
By AuntMinnie.com staff writers
September 21, 2004
Related Reading
Draxis Health books record revenues, August 12, 2004
Draxis ups gains in Q1, May 13, 2004
Draxis acquires remainder of Draxis Pharma, April 23, 2004
Draxis closes unit share deal, April 22, 2004
DraxImage, Isotope Products ink distribution deal, March 22, 2004
Copyright © 2004 AuntMinnie.com
